Human Recombinant EPO_产品中心_北京砺达辰生物科技有限公司

概要

Erythropoietin (EPO) is a glycoprotein growth factor that is produced primarily in the kidney in response to hypoxia or anemia. It is the principal physiological regulator of erythropoiesis. EPO promotes erythropoiesis by binding to a homodimeric cell surface receptor that activates JAK2/STAT5, PI3K/AKT, and MAPK pathways, and stimulates the proliferation and differentiation of erythroid progenitor cells (Jelkmann; Kuhrt & Wojchowski).

技术资料

Document Type	产品名称	Catalog #	Lot #	语言
Product Information Sheet	Human Recombinant EPO	78007, 78007.1, 78007.2	All	English
Safety Data Sheet	Human Recombinant EPO	78007, 78007.1, 78007.2	All	English

数据及文献

Data

(A) The biological activity of Human Recombinant EPO was tested by its ability to promote the proliferation of TF-1 cells. Cell proliferation was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which the cell proliferation is at 50% of maximum. The EC50 in the above example is less than 0.6 ng/mL. (B) Human Recombinant EPO stimulates the proliferation and differentiation of erythroid progenitor cells, and was validated by titration in a CFU assay on human bone marrow MNCs, using MethoCult™ SF H4236 (Catalog #04236). The total number of colonies at each EPO concentration was enumerated using STEMvision™ (Catalog #22006). (C) 5 μg of Human Recombinant EPO was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant EPO polypeptide has a predicted molecular mass of 18.4 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 26 - 36 kDa in SDS-PAGE.